Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

Benzinga · 3d ago
Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.